Shares of Aevi Genomic Medicine, Inc. (NASDAQ:GNMX) have been assigned an average broker rating score of 2.00 (Buy) from the three brokers that provide coverage for the company, Zacks Investment Research reports. One equities research analyst has rated the stock with a hold recommendation, one has given a buy recommendation and one has issued a strong buy recommendation on the company. Aevi Genomic Medicine’s rating score has declined by 14.3% in the last three months as a result of a number of analysts’ ratings changes.

Analysts have set a 1 year consensus target price of $6.38 for the company and are anticipating that the company will post ($0.17) earnings per share for the current quarter, according to Zacks. Zacks has also assigned Aevi Genomic Medicine an industry rank of 218 out of 265 based on the ratings given to its competitors.

Several research analysts have recently weighed in on the stock. Needham & Company LLC cut their price objective on shares of Aevi Genomic Medicine from $9.00 to $7.00 and set a “buy” rating on the stock in a report on Wednesday, August 16th. Jefferies Group LLC reiterated a “hold” rating and set a $1.50 price objective on shares of Aevi Genomic Medicine in a report on Thursday, September 28th.

In other Aevi Genomic Medicine news, insider Garry Arthur Neil bought 75,000 shares of the company’s stock in a transaction that occurred on Tuesday, October 17th. The stock was purchased at an average price of $1.26 per share, with a total value of $94,500.00. Following the transaction, the insider now owns 114,774 shares in the company, valued at $144,615.24. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO Michael F. Cola bought 119,047 shares of the company’s stock in a transaction that occurred on Tuesday, October 17th. The shares were acquired at an average cost of $1.26 per share, with a total value of $149,999.22. Following the transaction, the chief executive officer now owns 218,483 shares in the company, valued at approximately $275,288.58. The disclosure for this purchase can be found here. In the last three months, insiders have purchased 625,440 shares of company stock valued at $787,433. Corporate insiders own 15.20% of the company’s stock.

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Wells Fargo & Company MN increased its position in Aevi Genomic Medicine by 433.7% during the 3rd quarter. Wells Fargo & Company MN now owns 130,662 shares of the biotechnology company’s stock worth $165,000 after purchasing an additional 106,178 shares in the last quarter. Northern Capital Management LLC increased its position in Aevi Genomic Medicine by 43.6% during the 3rd quarter. Northern Capital Management LLC now owns 152,300 shares of the biotechnology company’s stock worth $192,000 after purchasing an additional 46,250 shares in the last quarter. Birchview Capital LP increased its position in Aevi Genomic Medicine by 88.2% during the 2nd quarter. Birchview Capital LP now owns 128,000 shares of the biotechnology company’s stock worth $170,000 after purchasing an additional 60,000 shares in the last quarter. LMR Partners LLP acquired a new stake in Aevi Genomic Medicine during the 2nd quarter worth approximately $149,000. Finally, TIAA CREF Investment Management LLC increased its position in Aevi Genomic Medicine by 16.7% during the 1st quarter. TIAA CREF Investment Management LLC now owns 97,719 shares of the biotechnology company’s stock worth $182,000 after purchasing an additional 13,966 shares in the last quarter. 20.99% of the stock is owned by hedge funds and other institutional investors.

Shares of Aevi Genomic Medicine (GNMX) traded up $0.02 during mid-day trading on Thursday, hitting $1.49. 72,000 shares of the stock traded hands, compared to its average volume of 479,195. Aevi Genomic Medicine has a 1-year low of $0.98 and a 1-year high of $6.89.

Aevi Genomic Medicine (NASDAQ:GNMX) last announced its quarterly earnings data on Thursday, November 2nd. The biotechnology company reported ($0.23) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.22) by ($0.01). During the same period last year, the firm posted ($0.29) EPS. research analysts anticipate that Aevi Genomic Medicine will post -0.86 earnings per share for the current year.

TRADEMARK VIOLATION WARNING: This piece of content was first reported by Daily Political and is the property of of Daily Political. If you are accessing this piece of content on another publication, it was illegally copied and republished in violation of United States and international copyright legislation. The legal version of this piece of content can be read at https://www.dailypolitical.com/2017/11/16/brokerages-anticipate-aevi-genomic-medicine-inc-gnmx-to-post-0-17-earnings-per-share.html.

About Aevi Genomic Medicine

Aevi Genomic Medicine, Inc, a clinical stage biopharmaceutical company, researches and develops novel therapies for pediatric onset and life-altering diseases in the United States. Its lead product candidates include AEVI-001, a glutamatergic neuromodulator, which is in Phase II/III SAGA trial for a genetically-defined subset of adolescent attention deficit hyperactivity disorder patients with specific mutations in their metabotropic glutamate receptor gene network; and AEVI-002, an anti-light monoclonal antibody that is in Phase I clinical trial for use in severe pediatric onset crohn’s disease.

Get a free copy of the Zacks research report on Aevi Genomic Medicine (GNMX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Aevi Genomic Medicine Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aevi Genomic Medicine Inc. and related companies with MarketBeat.com's FREE daily email newsletter.